Im­muno­Gen push­es read­out of rare blood can­cer tri­al to 2024

While Im­muno­Gen has an up­com­ing de­ci­sion date with the FDA for its lead ovar­i­an can­cer drug in No­vem­ber, the an­ti­body drug con­ju­gate-fo­cused biotech re­port­ed this …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER